Navigation Links
NYSCF and NIH create cell models of rare and undiagnosed diseases
Date:11/21/2013

NEW YORK, NY (November 21, 2013) In what is anticipated to be a major step forward for rare disease research, The New York Stem Cell Foundation (NYSCF) Research Institute is partnering with the National Institutes of Health (NIH) Undiagnosed Disease Program (UDP). NYSCF scientists will generate stem cell lines from 100 patients in the UDP and collaborate with UDP researchers to better understand and potentially treat select rare diseases. While working collaboratively under this agreement, neither NIH nor NYSCF will receive funding. This partnership will leverage investments made using government (NIH) and private (NYSCF) dollars to ensure that research into rare diseases will move forward efficiently and effectively.

In 2008, the NIH developed the UDP to study patients with rare diseases, track their progression and symptoms, and obtain biological specimen samples to help pinpoint the root cause of their ailments. These patients, whose disorders have long-eluded diagnosis, provide skin samples that will be used to generate stem cell lines on the NYSCF Global Stem Cell Array, a robotic technology that automates the derivation process. "The NYSCF Global Stem Cell Array provides us with the critical ability to produce accurate cell models of these rare diseases, serving as 'windows onto disease,'" said Susan L. Solomon, CEO of NYSCF.

"This collaborative effort has the potential to create new disease models that will reveal whether candidate gene variants are responsible for a patient's disease," said Dr. William Gahl, Director of the NIH UDP. "In addition, the stem cells can illustrate new mechanisms with broad applicability to more common disorders." Gahl also noted that this venture may eventually be expanded to other centers within the Undiagnosed Diseases Network. The network is a group of 5 to 7 clinical sites, in addition to the UDP, that the NIH Common Fund will establish within the coming year.

NYSCF scientists will create
'/>"/>

Contact: David McKeon
dmckeon@nyscf.org
212-365-7440
New York Stem Cell Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. NYSCF scientists develop 3-D stem cell culture technique to better understand Alzheimers disease
2. NYSCF scientists develop new protocol to ready induced pluripotent stem cell clinical application
3. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
4. Scientists discover switch in plants to create flowers
5. Climate change may create price volatility in the corn market, say Stanford and Purdue researchers
6. Putting plants online: 4 leading botanical gardens to create first online catalog of all plants
7. Botanical institutions announce plans to create first online World Flora
8. Engineers use droplet microfluidics to create glucose-sensing microbeads
9. U-M biologist plays key role in effort to create first comprehensive tree of life
10. University of Hawaii Cancer Center researchers create new anti-cancer drug
11. A non-invasive intracellular thermometer with fluorescent proteins has been created
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint ... FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... The sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of approximately 2,200 ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... from two research teams at the Polytechnic Institute of ... be used to understand and influence the complex swimming ... Porfiri, associate professor of mechanical and aerospace engineering at ... PLOS ONE . These studies are the ...
... scent marking to advertise their territory they urinate at ... It has been suggested that markings serves to attract females ... males, scent marks appear to be a secondary sexual trait, ... mate. When male house mice are subordinate or sick, for ...
... regarded as a fully-paid up member of the junk food ... versions found on supermarket shelves or delivered to your door ... and a little cheese, combined to form a traditional, healthy ... new members to their posse salt and saturated fat. ...
Cached Biology News:The secret's in the (robotic) stroke 2The secret's in the (robotic) stroke 3Scent marking 2Pizza perfect! A nutritional overhaul of 'junk food' and ready-meals is possible 2Pizza perfect! A nutritional overhaul of 'junk food' and ready-meals is possible 3
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Germany, March 17 The rating,agency Moody,s has ... Ba3 to,Ba2 with "Outlook stable"., As a ... and its,refinancing possibilities are substantially enhanced. Moody,s justifies,this ... profile as,a result of successful acquisitions and in ...
... MASI ), the inventor of Pulse CO-Oximetry and Measure-Through,Motion ... scheduled,to present at the Citi Investment Research 5th Annual Small ... NV on Wednesday, March,19, 2008 at 2:25 p.m. PT. Joe ... Vice President and CFO, will be presenting., A live ...
... 19 at 10:00 AM EDT, CEDAR KNOLLS, N.J., ... will host a conference call discussing,its financial results for ... Wednesday, March 19, at 10:00 AM EDT., The ... through the,company,s Web site at: http://www.emisphere.com . The ...
Cached Biology Technology:Moody's Raises Rating for Gerresheimer 2Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference 2Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results 2
... of a Hybridizer and UV Crosslinker (254nm UV) ... , This unique, new design for the ... one location , Hybridizer and Crosslinker portions ... , The Crosslinker is also available as ...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
... Jouan RCT series of refrigerated cold traps ... trapping of low volatility/aqueous solvents or high ... and other vacuum concentrators/centrifugal evaporators. Also used ... systems such as used in electron microscopes. ...
Biology Products: